Lisa Golding-Granado
Internal Medicine · Shrewsbury, NJNPI 1538163928
Payments from drug & device makers
Across 92 payments — averaging $89.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$6K
- Merz North America, Inc.$1K
- Novo Nordisk$233
- AstraZeneca$162
- Antares Pharma, Inc.$68
- Kowa Pharmaceuticals America, Inc.$68
- plus $382 from 12 others
What the payments were for
- Speaking & faculty fees$5,00061%
- Food & beverage$3,19139%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 39 | $5,798 |
| Merz North America, Inc. | 7 | $1,482 |
| Novo Nordisk | 11 | $233 |
| AstraZeneca | 3 | $162 |
| Antares Pharma, Inc. | 4 | $68 |
| Kowa Pharmaceuticals America, Inc. | 5 | $68 |
| Lilly USA, LLC | 4 | $61 |
| Pfizer | 3 | $49 |
| Exact Sciences | 2 | $49 |
| Johnson & Johnson | 3 | $49 |
| Galderma Laboratories, L.p. | 3 | $39 |
| Intra-sana Laboratories | 2 | $31 |
| Abbott | 1 | $21 |
| Astellas Pharma US Inc | 1 | $20 |
| GSK | 1 | $19 |
| Alkermes, Inc. | 1 | $16 |
| IBSA Pharma Inc. | 1 | $15 |
| Halozyme Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,191 in reported general payments places this provider in the 90th percentile of 4,032 internal medicine providers in New Jersey.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 35 | $33,284 |
| MounjaroTirzepatide | 28 | $32,135 |
| BrilintaTicagrelor | 12 | $5,253 |
| ElmironPentosan Polysulfate Sodium | 11 | $3,619 |
| Oxycodone Hcl | 83 | $1,763 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 48 | $1,339 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 46 | $995 |
| Fentanyl | 12 | $932 |
| Rosuvastatin Calcium | 48 | $818 |
| Asa-Butalb-Caffeine-CodeineCodeine/Butalbital/Asa/Caffein | 13 | $799 |
| Ondansetron OdtOndansetron | 14 | $747 |
| Butalbital-Acetaminophen-CaffeButalb/Acetaminophen/Caffeine | 14 | $667 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 18 | $596 |
| Levothyroxine Sodium | 53 | $558 |
| Hydromorphone Hcl | 11 | $422 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $233 | $33,28435 claims |
| Lilly USA, LLCMounjaro | $61 | $32,13528 claims |
| AstraZenecaBrilinta | $162 | $5,25312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,032 internal medicine providers in New Jersey.
Other internal medicine in Shrewsbury
- Sanjiv SharmaToms River$33.9M
- Jeffrey CarsonNew Brunswick$13.8M
- Samer HaddadHamilton$6.8M
- Magdy ShenoudaWall$3.7M
- Samar HameedLivingston$3.6M
- Jane RohlfTrenton$2.7M
- Mohammed NisarEdison$2.6M
- Michael CasserNew Milford$2.2M
- Sumitha ReddyHamilton$2M
- Helio PedroNewark$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.